An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels

Expert Opinion on Investigational Drugs

Volumn 20, Issue 8, 2011, Pages 1039-1045

  Wang, Zheng ^a   Hu, Jie ^a   Qiu, Shuang Jian ^a   Huang, Xiao Wu ^a   Dai, Zhi ^a   Tan, Chang Jun ^a   Zhou, Jian ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Phosphorylated ERK; Recurrence and metastasis; Sorafenib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIFESPAN; LIVER CANCER; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960348649     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.588598     Document Type: Article

References (27)

1. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37:S88-94
2. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;20:S1-12
3. Tang ZY, Yu YQ, Zhou XD, et al. Progress and prospects in hepatocellular carcinoma surgery. Ann Chir 1998;52:558-63 (Pubitemid 28331428)
4. Addeo R, Caraglia M, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs 2009;18(3):373-8
5. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg 2003;237:536-43
6. Regimbeau JM, Abdalla EK, Vauthey JN, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004;85:36-41 (Pubitemid 38036738)
7. Kohno H, Nagasue H, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996;43:1405-9 (Pubitemid 27007323)
8. Lai EC, Lo CM, Fan ST, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998;133:183-8 (Pubitemid 28092919)
9. Lin SM, Lin CJ, Hsu CW. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2003;100:376-82
10. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54 (Pubitemid 44970357)
11. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801 (Pubitemid 29110405)
12. Yamamoto M, Arii S, Sughara K, et al. Adjuvant oral chemotherapy after curative resection of hepatocellular carcinoma. Br J Surg 1996;83:336-40 (Pubitemid 26083165)
13. Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmfur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997;24:S6-18
14. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-7
15. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37
16. Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
18. Zhang Z, Zhou X, Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009;7:41
19. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74 (Pubitemid 46295136)
20. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19
21. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310 (Pubitemid 46763022)
22. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
23. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
24. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bimmediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-18 (Pubitemid 351552630)
25. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300 (Pubitemid 46630787)
26. Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011;53:483-92
27. Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010;79:62-6